TherapeuticsMD, Inc. TXMD
Last close
2.21
2026-09-04
Market cap
$25.6M
2026-06-30 share count
52-week range
0.99 - 2.95
Valuation FY2025 figures against the last close
P/S8.5x
P/E—
P/FCF10.4x
EV/EBITDA—
Dividend yield—
Diluted EPS-0.05
Where the revenue comes from as reported in the latest 10-K
Revenue by geography
- United States
- Non-U.S.
| Region | FY2025 | FY2024 |
|---|---|---|
| United States | $1.8M | $1.1M |
| Non-U.S. | $1.2M | $638.0K |
As the company reported it, from the “Segment Reporting - Schedule of Total Revenue (Details)” note of its latest 10-K. Every figure here has been checked against the total revenue the same filing reported. Regions are the filer's own and are not mapped onto a standard list — one company's “Americas” and another's “United States” are different areas, and making them look comparable would mean making at least one of them wrong. Slices under 1% are folded into “Other”.
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.0M | $1.8M | $1.3M | $70.0M | $2.6M | $64.9M | $49.6M | $16.1M | $16.8M | $19.4M |
| Cost of revenue | — | — | — | $1.4M | $1.4M | $16.0M | $6.3M | $2.7M | $2.6M | $4.2M |
| Gross profit | — | — | $1.3M | $68.6M | $1.2M | $48.9M | $43.3M | $13.4M | $14.1M | $15.2M |
| R&D | — | — | — | — | $7.1M | $10.4M | $19.8M | $27.3M | $33.9M | $53.9M |
| SG&A | $6.9M | $6.1M | $8.9M | $56.7M | $80.7M | $77.0M | $60.5M | $116.0M | $57.7M | $51.3M |
| Total operating expenses | $7.4M | $7.9M | $9.8M | $67.4M | $80.7M | $204.4M | $194.5M | $143.6M | $91.8M | $105.4M |
| Operating income | -$4.4M | -$6.1M | -$8.5M | $1.2M | -$79.6M | -$155.5M | -$151.2M | -$130.2M | -$77.6M | -$90.3M |
| Interest expense | — | — | $300.0K | $200.0K | $32.9M | $28.6M | $17.4M | $4.7M | — | — |
| Pre-tax income | -$653.0K | -$2.3M | -$7.7M | $1.1M | -$79.3M | -$183.5M | -$176.1M | -$132.6M | -$76.9M | -$89.9M |
| Income tax | — | $31.0K | $43.0K | — | — | — | — | — | — | — |
| Net income | -$569.0K | -$2.2M | -$10.3M | $112.0M | -$172.4M | -$183.5M | -$176.1M | -$132.6M | -$76.9M | -$89.9M |
| EPS, basic | -0.05 | -0.19 | -0.99 | 12.41 | -21.66 | — | — | — | — | — |
| EPS, diluted | -0.05 | -0.19 | -0.99 | 11.96 | -21.66 | -0.67 | -0.72 | -0.59 | -0.37 | -0.46 |
| Shares, diluted (wtd. avg.) | 11.6M | 11.5M | 10,441 | 9.4M | 8.0M | 275.6M | 246.4M | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $7.5M | $5.1M | $4.3M | $49.3M | $64.9M | $80.5M | $160.8M | $161.6M | $127.1M | $131.5M |
| Receivables | — | — | — | — | $36.2M | $32.4M | $24.4M | $11.1M | $4.3M | $4.5M |
| Inventory | — | — | — | — | $7.6M | $8.0M | $11.9M | $3.3M | $1.5M | $1.1M |
| Total current assets | $14.4M | $12.3M | $11.8M | $55.4M | $119.5M | $128.4M | $208.4M | $186.8M | $139.6M | $139.4M |
| Property, plant and equipment | — | — | — | $78.0K | $823.0K | $1.9M | $2.5M | $472.7K | $437.1K | $516.8K |
| Other intangibles | $3.8M | $4.3M | $6.1M | $6.9M | $7.1M | $41.4M | $5.3M | $4.1M | $3.1M | $2.4M |
| Total assets | $37.7M | $38.8M | $43.3M | $90.5M | $169.5M | $181.6M | $266.0M | $212.0M | $143.2M | $142.5M |
| Accounts payable | $377.0K | $258.0K | $27.0K | $2.2M | $3.4M | $21.1M | $19.2M | $22.7M | $4.1M | $7.4M |
| Short-term debt | — | — | — | — | $188.3M | — | — | — | — | — |
| Total current liabilities | $4.8M | $5.2M | $6.9M | $46.8M | $252.9M | $59.2M | $53.0M | $41.1M | $13.3M | $15.0M |
| Long-term debt | — | — | — | — | $0 | $237.7M | $194.6M | $73.4M | — | — |
| Total liabilities | $10.8M | $11.5M | $14.0M | $55.3M | $263.1M | $305.6M | $256.8M | $114.5M | $13.3M | — |
| Retained earnings | -$952.4M | -$951.8M | -$949.6M | -$939.4M | -$1.05B | -$878.9M | -$695.4M | -$519.3M | -$386.7M | -$309.7M |
| Total equity | $26.9M | $27.4M | $29.3M | $35.1M | -$93.6M | -$124.0M | $9.2M | $97.5M | $129.9M | $127.5M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $2.5M | $1.2M | -$23.1M | $9.4M | -$55.1M | -$159.5M | -$165.7M | -$106.8M | -$76.2M | -$69.1M |
| Depreciation and amortisation | — | — | $100.0K | $600.0K | $400.0K | $800.0K | $400.0K | $181.4K | $141.6K | $77.9K |
| Stock-based compensation | $75.0K | $264.0K | $1.3M | $11.6M | $18.1M | $10.7M | $10.7M | $8.7M | $6.9M | $17.4M |
| Capital expenditure | — | — | — | — | $34.0K | $207.0K | $2.5M | $217.0K | $61.8K | $396.2K |
| Investing cash flow | — | — | — | -$355.0K | -$2.2M | -$1.6M | -$23.9M | -$21.5M | -$827.1K | -$1.3M |
| Financing cash flow | — | — | $3.2M | -$235.2M | $129.6M | $80.7M | $188.8M | $162.8M | $72.6M | $137.2M |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001213900-26-037918.
Plot the figures US dollars
Income statement
Revenue
Cost of revenue
Gross profit
R&D
SG&A
Total operating expenses
Operating income
Interest expense
Pre-tax income
Income tax
Net income
EPS, basic
EPS, diluted
Shares, diluted (wtd. avg.)
- Total current assets
- Total operating expenses
- Total current liabilities
- Financing cash flow
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total current assets | $139.4M | $139.6M | $186.8M | $208.4M | $128.4M | $119.5M | $55.4M | $11.8M | $12.3M | $14.4M |
| Total operating expenses | $105.4M | $91.8M | $143.6M | $194.5M | $204.4M | $80.7M | $67.4M | $9.8M | $7.9M | $7.4M |
| Total current liabilities | $15.0M | $13.3M | $41.1M | $53.0M | $59.2M | $252.9M | $46.8M | $6.9M | $5.2M | $4.8M |
| Financing cash flow | $137.2M | $72.6M | $162.8M | $188.8M | $80.7M | $129.6M | -$235.2M | $3.2M | — | — |
Recent filings and events
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Results announced Item 2.02
- Regulation FD disclosure Item 7.01
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Results announced Item 2.02
- Regulation FD disclosure Item 7.01
- Auditor changed The company changed auditors. Sometimes routine; historically one of the more reliable warnings that something is wrong. Item 4.01
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Results announced Item 2.02
- Regulation FD disclosure Item 7.01
- Results announced Item 2.02
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AKTX | Akari Therapeutics Plc | $1.79T | — | — |
| LLY | ELI LILLY & Co | $1.08T | 50.1x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $663.28B | 25.0x | 6.0% |
| ONC | BeOne Medicines Ltd. | $529.55B | 1,885.6x | 40.2% |
| ABBV | AbbVie Inc. | $453.19B | 108.7x | 8.6% |
| MRK | Merck & Co., Inc. | $370.89B | 20.6x | 1.3% |
| ABT | ABBOTT LABORATORIES | $188.69B | 29.1x | 5.7% |
| PFE | PFIZER INC | $162.16B | 20.9x | -1.6% |